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Annually  inﬂuenza  virus  infections  are  responsible  for hospitalization  and  mortality,  especially  in  high
risk  groups.  Constant  antigenic  changes  in  seasonal  inﬂuenza  viruses  resulted  from  antigenic  shifts  and
antigenic  drifts,  enable  emerging  of  novel  virus  subtypes  that  may  reduce  current  vaccine  efﬁcacy  and
impose  the continuous  revision  of  vaccine  component.  Currently  available  vaccines  are usually  limited
by  their  production  processes  in terms  of rapid  adaptation  to  new  circulating  subtypes  in high  quanti-
ties  meeting  the  global  demand.  Thus,  new  approaches  to rapidly  manufacture  high  yields of  inﬂuenza
vaccines  are  required.  New  technologies  to  reach  maximal  protection  with  minimal  vaccine  doses  also
need  to be developed.
In  this  study,  we  evaluated  the  systemic  and local  immunogenicity  of  a  new  double-adjuvanted
inﬂuenza  vaccine  administered  at the  site  of  infection,  the  respiratory  tract. This vaccine  combines  a
plant-produced  H1N1  inﬂuenza  hemagglutinin  antigen  (HAC1),  a silica  nanoparticle-based  (SiO2)  drug
delivery  system  and  the  mucosal  adjuvant  candidate  bis-(3′,5′)-cyclic  dimeric  guanosine  monophos-
phate  (c-di-GMP).  Mice  were  vaccinated  by intratracheal  route  with  HAC1/SiO2 or  HAC1/c-di-GMP
(single-adjuvanted  vaccine)  or HAC1/SiO2/c-di-GMP  (double-adjuvanted  vaccine)  and evaluated  for
target-speciﬁc  immune  responses,  such  as hemagglutination  inhibition  and hemagglutinin-speciﬁc  IgG
titers, as  well  as  local  antibody  (IgG  and  IgA)  titers  in  the  bronchoalveolar  lavage  (BAL).  Furthermore,
the  HAC1-speciﬁc  T-cell  re-stimulation  potential  was  assessed  using  precision-cut  lung slices  (PCLS)  of
vaccinated  mice.
The  double-adjuvanted  vaccine  induced  high  systemic  antibody  responses  comparable  to  the systemic
vaccination  control.  In  addition,  it induced  local  IgG  and  IgA  responses  in  the  BAL.  Furthermore,  HAC1
induced  a  local  T-cell  response  demonstrated  by elevated  IL-2  and IFN-  levels  in  PCLS  of c-di-GMP-
vaccinated  mice  upon  re-stimulation.
Overall,  the  present  study  showed  the  potential  of  the double-adjuvanted  vaccine  to  induce  systemic
humoral  immune  responses  in  intratracheally  vaccinated  mice.  Furthermore,  it induced  a strong  mucosal
immune  response,  with  evidence  of  antigen-primed  T-cells  in the lung.
©  2014  The  Authors.  Publis
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1. Introduction
Annual inﬂuenza-associated cases of hospitalization and up
to 500,000 deaths during frequent virus outbreaks and sporadic
pandemics illustrate the serious health burden of inﬂuenza virus
infections [1]. The high mutational rate of the virus and fre-
quency of interspecies transmission and/or zoonosis leading to new
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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irus subtypes makes inﬂuenza infections highly unpredictable
2,3]. Therefore, there is a need of developing novel and effective
nﬂuenza vaccines.
Traditionally, only systemic administration of inactivated
nﬂuenza vaccines, mostly intramuscularly, has been used. In 2003
lumist®, the ﬁrst nasal inﬂuenza vaccine with live attenuated
nﬂuenza viruses, has been approved in the US [4], which pro-
ects locally at the site of virus entry and infection. An advantage
f delivering vaccines via the respiratory route is, besides the
nductions of local immune responses at virus settlement, the non-
nvasive application which is likely to increase public compliance.
owever, it has been described that intranasal antigen admin-
stration induces poor immune responses when applied without
n appropriate mucosal adjuvant [5]. Thus, many new effective
ucosal adjuvants are in preclinical development (s. review [6]).
n 2007, bis-(3′,5′)-cyclic dimeric guanosine monophosphate (c-
i-GMP) was introduced as a mucosal adjuvant with promising
ctivity [7]. Madhun et al. showed that c-di-GMP improved the
mmunogenicity of an intranasally delivered subunit inﬂuenza vac-
ine, compared to antigen only, by inducing strong mucosal and
ystemic immune responses [8]. Additionally, the authors showed
hat intranasal administration of the c-di-GMP adjuvanted antigen
nduced protective antibody titers and cellular immune responses
hat far exceeded the responses induced by intramuscular admin-
stration of the same vaccine [8]. Moreover, Svindland et al. tested
accination with c-di-GMP combined with a second adjuvant,
hitosan, and showed that vaccination with the combination of
hese molecules can further improve the humoral and cellular
mmune responses against target antigens [9]. Besides its adju-
antive effects, Chitosan is used as an intranasal delivery system.
ther drug delivery systems such as silica nanoparticle (NP) have
lso been previously shown to have adjuvant properties [10,11].
ecently, we have shown that a combination of a plant-produced
ecombinant hemagglutinin (HA) antigen from the H1N1 inﬂuenza
irus A/California/04/09 (HAC1) with silica-NP (SiO2) was able to
ecall a previously established immune response in human lung
issue [12]. Manufacturing of recombinant proteins in plants for
nﬂuenza vaccine development evolved as an alternative to the
onventional egg-based vaccine production to overcome the lim-
tations in quantity and time consumption [13]. This bottleneck
f egg-produced vaccines can have serious consequences during
nﬂuenza pandemics, when the production of sufﬁcient amounts
f vaccine in an adequate time frame to serve the global market
ould be difﬁcult.
Regarding the need of rapidly produced vaccines in times of
andemics and the time consuming limitation of the egg-based vac-
ines, the here presented study tested the recombinant antigen of
 highly immunogenic H1N1 strain responsible for the 2009/2010
andemic. Furthermore, the study extends the published work with
AC1 and SiO2 and evaluates the immunogenicity of this vaccine
ormulation when combined with c-di-GMP and administered at
he site of virus entry. Overall, it showed the potential of the c-di-
MP/SiO2 double-adjuvanted vaccine to induce systemic humoral
nd strong mucosal immune responses, with IgA in the airways.
urthermore, it presented evidence of antigen-primed T-cells in
he lung in intratracheally vaccinated mice.
. Materials and methods
.1. AnimalsFemale wild-type BALB/c mice aged 6–8 weeks (Charles River,
ulzfeld, Germany) were kept at an animal facility under con-
entional housing conditions (22 ◦C, 55% humidity, 12-h day/night
ycle) with food and tap water ad libitum. The randomized study2 (2014) 3216–3222 3217
was approved by a local agency (Application-No. 33.9-42502-
04-11/0465) and conducted according to the German Animal
Protection law.
2.2. Media
Reagents were, if not stated otherwise, purchased from
Sigma–Aldrich (Munich, Germany). Phosphate buffered saline
(PBS) without Ca2+ and Mg2+, pH 7.4, Dulbecco’s Modiﬁed Eagle’s
Medium/Nutrient Mixture F-12 HAM (DMEM) with l-glutamine,
15 mM HEPES and 7.5% w/v  sodium bicarbonate without phenol
red, pH 7.2–7.4, RPMI 1640 and Earle’s Balanced Salt Solution (EBSS)
were obtained from Gibco (Darmstadt, Germany). Cell/tissue cul-
tivation medium was  supplemented with 100 U/mL penicillin and
100 g/mL streptomycin.
2.3. Vaccine and adjuvants
HAC1 was produced as previously described [14]. Brieﬂy, the
HA nucleotide sequence, encompassing amino acids 18–530 of the
A/California/04/09 inﬂuenza strain (H1N1, NCBI accession number
ACQ76318.1) were optimized for expression in plants and syn-
thesized. The optimized HA sequence contains a 6× His afﬁnity
puriﬁcation tag and the ER retention signal KDEL at the C-terminus.
This gene was  inserted into the pGRD4 launch vector and trans-
formed into Agrobacterium tumefaciens. The transformed bacterium
was introduced into hydroponically grown Nicotiana benthamiana
by vacuum inﬁltration and leaf tissues were harvested, homoge-
nized, extracted, ﬁltered and chromatographically puriﬁed after
a one-week growing period [14]. Aliquots of puriﬁed HAC1 were
kept in PBS at −80 ◦C until usage. For silica-NP, DMEM and SiO2
nanopowder (HDK 200, Wacker Chemie, Germany) were mixed and
dispersed by ultrasonic sonotrode. The production of c-di-GMP has
been described before [15,16]. Lyophilized c-di-GMP was stored
at −20 ◦C. Immediately prior to immunization, HAC1 was  admixed
with the adjuvant and/or silica-NP and swirled ≥ 10 min  on an over-
head shaker to ensure complete mixing.
2.4. Vaccination and sample collection
Mice were immunized on days 0 and 21 with either 5 g antigen
(HAC1), single- or double-adjuvanted vaccine (5 g HAC1/10 g
SiO2; 5 g HAC1/7.5 g c-di-GMP; 5 g HAC1/10 g SiO2/7.5 g
c-di-GMP) by intratracheal route (50 l). For intratracheal immu-
nization mice were tilted (∼45◦) and the vaccine administered into
the deep lung with subsequent insufﬂation with an air bolus. A sys-
temic control group to ensure the effectiveness of the vaccination
protocol, received 1 g HAC1 adsorbed on aluminum hydroxide
(Alum) intraperitoneally (200 l). Blood was  obtained by retrob-
ulbar sampling and sera were collected on days 0, 21, 35, and
49 to determine HA-speciﬁc antibody response by hemagglutina-
tion inhibition (HAI) and enzyme-linked immunosorbent (ELISA)
assays. On day 49, mice were sacriﬁced with an intraperitoneal
overdosing of pentobarbital-Na (Merial, Hallbergmoos, Germany)
and cutting the Vena cava inferior. BAL ﬂuids, agarose-ﬁlled lungs,
and spleens were sampled and used for immunoglobulin (Ig) mea-
surements and re-stimulation assays.
2.5. HAI assay
Collected sera were treated with a receptor-destroying enzyme
(Denka Seiken, Japan). HAI assay was performed using 0.75%
turkey erythrocytes and A/California/07/09 × 179A virus (CDC
#2009713114) with an initial serum dilution of 1:20 as described
previously [14]. HAI endpoint titers were determined as reciprocal
3218 V. Neuhaus et al. / Vaccine 32 (2014) 3216–3222
Fig. 1. Titers of hemagglutination inhibition (HAI) antibody and antigen-speciﬁc IgG in sera of vaccinated mice. Mice were vaccinated on days 0 and 21 intratracheally with
5  g HAC1 only, admixed with a single adjuvant (HAC1/SiO2 or HAC1/c-di-GMP), or admixed with two  adjuvants (HAC1/SiO2/c-di-GMP) as the double-adjuvanted vaccine.
The  control group received 1 g HAC1 formulated with Alum intraperitoneally (i.p.). On days 0, 21, 35 and 49, blood was drawn retrobulbarly from the vaccinated mice
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ntigen  only; xp < 0.05, comparison of vaccination i.t. vs. i.p. (HAC1/SiO2/c-di-GMP 
n  = 5). HAC1: plant-derived recombinant hemagglutinin protein, SiO2 = silica nanop
f the highest serum dilution causing complete HAI. Seroconver-
ion in vaccinated animals was deﬁned as an HAI antibody titer at
 serum dilution of ≥ 1:40 [17,18].
.6. Antibody measurement
HA-speciﬁc serum IgG antibodies and nasal IgG and IgA were
ssessed using ELISA assay, as previously described [19]. Brieﬂy,
LISA plates were coated with inactivated A/California/07/09 virus
nd samples of BAL or serum were tested in series of two- or
our-fold dilutions. Antigen-speciﬁc IgG and IgA were detected
sing horseradish peroxidase-conjugated goat anti-mouse IgG or
gA antibody (Jackson Immunoresearch Laboratories Inc., PA, USA),
espectively. Endpoint titers were determined as reciprocal serum
ilutions that gave mean optical density (OD) values three times
reater than those from pre-immune sera at a 1:100 or 1:50 dilution
or IgG and IgA, respectively.
.7. Splenocyte proliferation assay
Isolated splenocytes (1 × 105 cells) of vaccinated mice were
ncubated in 96-well round bottom plates with RPMI supple-
ented with 5% fetal bovine serum, containing 10 g/mL HAC1
r PBS (negative control) at 37 ◦C for 72 h. Proliferation was mea-
ured as described before [20]. Cells were pulsed with 5 Ci/mL
H-thymidine (Amersham Buchler, Braunschweig, Germany) for
8 h and harvested on ﬁlter mats (Canberra-Packard, Dreieich,
ermany). A Topcount Microplate Scintillation Counter (Canberra-
ackard, Dreieich, Germany) measured 3H-thymidine-positive
ells as counts per minute.
.8. Antigen stimulation of precision-cut lung slices (PCLS)
Murine PCLS were prepared as described before [21,22]. Two
CLS (approx. 300 m thick) per well were treated with 10 g/mL
AC1 or medium (non-stimulated) and cultured under cell culture
onditions (37 ◦C, 5% CO2 and 95% air humidity) for 24 h. Super-
atant was collected and stored at −80 ◦C until use.nted as mean ± SEM. **p < 0.01 and ***p < 0.001, comparison with vaccination with
C1-Alum) using Kruskal–Wallis test and Dunn’s multiple comparison post hoc test
es, c-di-GMP: bis-(3′ ,5′)-cyclic dimeric guanosine monophosphate.
2.9. Cytokine measurement
Cytokines interleukin (IL)-2, interferon-gamma (IFN-), IL-5,
and IL-10 in the supernatant of re-stimulated PCLS were mea-
sured using the murine Th1/Th2 tissue culture kit from Meso Scale
Discovery (MSD) Assays (Gaithersburg, MD,  USA). The assay was
performed and results were analyzed according to manufacturer’s
speciﬁcations using MSD  plates, MSD  Sector Imager 2400, and
Discovery workbench software. Total protein concentrations were
measured in PCLS lysates using the BCA Protein Assay kit (Pierce,
Rockford, IL, USA) [12]. Cytokines were correlated to total protein
(ng/mg) and compared to the non-stimulated cytokine baseline
level as fold induction.
2.10. Statistical analysis
Statistical analyses were performed by either the
Kruskal–Wallis test with Dunn’s multiple comparison post hoc
tests or by the Mann–Whitney test using GraphPad 4.03 (GraphPad,
San Diego, CA, USA). Data were expressed as mean ± standard error
of the mean (SEM) or median ± quartiles. Differences between
treatment groups and controls were considered statistically sig-
niﬁcant at p < 0.05. The number of mice is indicated in the ﬁgure
legends.
3. Results
3.1. Intratracheal administration of double-adjuvanted HAC1
with SiO2 and c-di-GMP induced robust systemic antibody
responses
As main readout parameters for a systemic antibody response
HAI and HAC1-speciﬁc IgG titers were analyzed in the blood
of vaccinated mice. The non-adjuvanted group vaccinated with
HAC1 only did not develop detectable HAI or antigen-speciﬁc
IgG antibodies in the serum (Fig. 1). On the contrary, admin-
istration of HAC1 intraperitoneally with Alum served as a
positive control and induced very robust HAI (4096 ± 627.1;
Fig. 1A) and IgG (286,720 ± 75,248; Fig. 1B) antibody titers after
the second vaccination (day 35). Mice vaccinated with either
V. Neuhaus et al. / Vaccine 32 (2014) 3216–3222 3219
Fig. 2. Proliferation index of splenocytes upon re-stimulation with the recombi-
nant HAC1 antigen. Spleen cells of vaccinated mice were isolated on day 49 and
re-stimulated with 10 g/mL HAC1 followed by labeling with 3H-thymidine. The
proliferation indexes upon antigen stimulation and in the medium alone were
compared. Data are presented as mean ± SEM, **p < 0.01 compared to the prolifer-
ation index of non-stimulated splenocytes from the same animal; Mann–Whitney
t
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Fig. 3. Titers of antigen-speciﬁc IgG and IgA in the bronchoalveolar lavage (BAL)
ﬂuid of vaccinated mice. BAL from mice vaccinated with 5 g HAC1 or 10 g HAC1
was collected on day 49 and analyzed for HAC1-speciﬁc IgG and IgA (A and B).
Data are presented as Boxplot and whiskers median ± quartiles (n = 5) and com-
pared using the Kruskal–Wallis test and Dunn’s multiple comparison post-hoc test.est (n = 5). HAC1: plant-derived recombinant hemagglutinin protein, SiO2 = silica
anoparticles, c-di-GMP: bis-(3′ ,5′)-cyclic dimeric guanosine monophosphate,
lum: Aluminum hydroxide, i.t.: intratracheally, i.p.: intraperitoneally.
AC1/SiO2 or HAC1/c-di-GMP developed low titers of HAI anti-
odies after the second vaccination (43 ± 30 and 12 ± 7; Fig. 1A),
s well as modest serum IgG titers following the booster dose
205 ± 81 and 2980 ± 1419; Fig. 1B). The group receiving the
ouble-adjuvanted vaccine, HAC1/SiO2/c-di-GMP, developed high
AI titers (770 ± 470; Fig. 1A) and antigen-speciﬁc IgG titers
43,840 ± 23,923; Fig. 1B).
.2. Addition of c-di-GMP adjuvant was necessary to induce
ntigen-speciﬁc splenocytes
To further evaluate the systemic immune response following
ntratracheal vaccination, the proliferation index of splenocytes
pon antigenic re-stimulation was assessed (Fig. 2). Splenocytes
solated from immunized mice were re-stimulated in vitro with
AC1 followed by 3H-thymidine labeling. The cell proliferation
evel was compared to non-stimulated splenocytes from the same
nimal. Results showed no detectable antigen-induced prolifer-
tion of splenocytes in the non-adjuvanted, positive control, or
he HAC1/SiO2 groups (HAC1: 1.2 ± 0.1; HAC1-Alum: 1.5 ± 0.2;
AC1/SiO2: 1.2 ± 0.2).
In contrast, in the single-adjuvanted group (HAC1/c-di-GMP)
he level of proliferation was two-fold compared to non-stimulated
plenocytes (2.2 ± 0.4) and the double-adjuvanted vaccine induced
he highest level of splenocyte proliferation (4.4 ± 1.7) upon HAC1
e-stimulation.
.3. The double-adjuvanted vaccine induced local IgG and IgA
ntibody responses in the BAL
Local immune responses in the lung were assessed by measur-
ng HA-speciﬁc IgG or IgA titers in BAL samples (Fig. 3A and B). The
on-adjuvanted group vaccinated with HAC1 only did not develop
etectable IgG or IgA in the BAL (baseline IgG/IgA level 25; Fig. 3A
nd B). In contrast, the positive control group (HAC1-Alum) showed
ntigen-speciﬁc IgG titers in the BAL (115 ± 37) comparable to
he double-adjuvanted group, while IgA levels were undetectable.
AC1/SiO2 or HAC1/c-di-GMP did not induce detectable IgG or IgA
n the BAL of immunized mice. However, addition of c-di-GMP to
AC1/SiO2 did induce detectable levels of IgG in 2/5 mice (115 ± 73;
ig. 3A) and in one mouse detectable levels of IgA (Fig. 3B).*p  < 0.05 and **p < 0.01, comparison to vaccination with antigen only. HAC1: plant-
derived recombinant hemagglutinin protein, SiO2 = silica nanoparticles, c-di-GMP:
bis-(3′ ,5′)-cyclic dimeric guanosine monophosphate, Alum: Aluminum hydroxide,
i.t.:  intratracheally, i.p.: intraperitoneally.
In order to ensure that the induction of mucosal IgA in the single
positive mouse was a result of vaccination, mice were immunized
with a higher antigen concentration (10 g HAC1) and the BAL was
examined for the presence of HAC1-speciﬁc IgG and IgA (Fig. 3A and
B). The non-adjuvanted group (10 g HAC1) showed no increased
local IgG or IgA titers (Fig. 3A and B). One mouse given HAC1/SiO2
developed mucosal IgG titers above baseline (30 ± 5 vs. 25) while
two mice developed detectable IgA (titer 45 ± 15 vs. 25). HAC1/c-
di-GMP induced elevated titers of mucosal IgG (135 ± 68) and IgA
(385 ± 172) with positive titers in 80% of the vaccinated mice.
Mice receiving HAC1/SiO2/c-di-GMP developed enhanced levels of
mucosal IgG (540 ± 271) and IgA (490 ± 283) in 100% of vaccinated
mice. Additionally, doubling the antigen dose increased IgG by 4.3-
fold (Fig. 3A).
3.4. Animals immunized with HAC1/SiO2/c-di-GMP showed a
T-cell immune response upon antigenic re-stimulation
To determine the local antigen-speciﬁc T-cell-mediated
immune response at the cytokine level, PCLS from vaccinated
3220 V. Neuhaus et al. / Vaccine 32 (2014) 3216–3222
Fig. 4. Secreted cytokine proﬁle by PCLS from different vaccinated mouse groups upon re-stimulation with the recombinant HAC1 antigen. PCLS from vaccinated mice
were  prepared 28 days post the last vaccination, re-stimulated with 10 g/mL HAC1 and cultured for 24 h. The secretion of IFN- (A), IL-2 (B), IL-5 (C) and IL-10 (D) was
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ann–Whitney test (n = 3). PCLS: precision-cut lung slices, HAC1: plant-derived rec
imeric guanosine monophosphate, Alum: Aluminum hydroxide, i.t.: intratracheall
ice were re-stimulated with HAC1. Cytokine secretion upon
ntigen stimulation was compared to the non-stimulated
ytokine baseline level and expressed as fold induction. The
on-adjuvanted group (HAC1 only) showed no altered IL-2
r IFN- expression upon antigen-stimulation compared to
on-stimulated PCLS (fold induction ≤ 2; Fig. 4A and B). The
ositive control mice, however, secreted low levels of IL-2 com-
ared with non-stimulated samples (fold induction 37 ± 35)
ut showed no increase in IFN- production (27 ± 27). Results
lso showed that in contrast to HAC1/SiO2, re-stimulation
ith HAC1/c-di-GMP did induce antigen-speciﬁc cells pro-
ucing IL-2 and IFN- (155 ± 60 and 244 ± 118, respectively).
dditionally, re-stimulation of PCLS from HAC1/SiO2/c-di-GMP
accinated mice also induced IL-2 and IFN- (262 ± 132-fold and
75 ± 138-fold).
No induction of IL-5 secretion was detected in the non-
djuvanted, positive control or HAC1/SiO2 vaccinated groups upon
ntigenic re-stimulation (fold induction ≤ 2; Fig. 4C). However, the
-di-GMP-adjuvanted HAC1 antigen induced cells to secret slightly
levated levels of IL-5 upon HAC1 re-stimulation (2.2 ± 0.1 and
.4 ± 0.1 for single- and double-adjuvanted, respectively) com-
ared to non-stimulated PCLS.pared to re-stimulation with medium alone of PCLS from the same animal using the
nant hemagglutinin protein, SiO2 = silica nanoparticles, c-di-GMP: bis-(3′ ,5′)-cyclic
 intraperitoneally, IL: Interleukin, IFN-: Interferon-gamma.
The release of the anti-inﬂammatory cytokine IL-10 was at base-
line levels in PCLS from the non-adjuvanted and positive control
groups (fold induction ≤ 2; Fig. 4D) as well as HAC1/SiO2 immu-
nized mice. In contrast, IL-10 levels were enhanced in PCLS samples
from HAC1/c-di-GMP as well as HAC1/SiO2/c-di-GMP vaccinated
mice, when re-stimulated with HAC1 (12 ± 4 and 7 ± 2, respec-
tively).
4. Discussion
The present study evaluated the systemic and local immuno-
genicity of a double-adjuvanted inﬂuenza vaccine (HAC1/SiO2/c-
di-GMP) delivered via the respiratory tract. The vaccine is intended
to be used as an inhalable needle-free vaccine targeting the upper
and lower respiratory tract. However, for the work described here,
we administered the vaccine intratracheally as a practical alter-
native to evaluate effects of the vaccine in the deeper lung before
conducting an inhalation study prior to the challenge experiments.
Minne and colleagues described the impact of vaccine delivery site
on the immune responses and concluded that targeting the lower
lungs for an inhaled inﬂuenza vaccination can induce systemic and
local immune responses most efﬁciently [23].
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Recent results with the NP-admixed antigen in a human lung tis-
ue model showed that HAC1/SiO2 was able to re-activate formerly
rimed T-cells [12]. Even though HAC1/SiO2 had a re-activating
otential in human PCLS, vaccination of mice intratracheally was
arely able to induce seroprotection (HAI titer >1:40). Moreover, it
id not induce any local immune response, such as antigen-speciﬁc
g secretion or T-cell induction upon re-stimulation, when admin-
stered at a lower antigen dose (5 g HAC1). However, addition of
he mucosal adjuvant c-di-GMP to HAC1/SiO2 induced HAI and IgG
ntibodies and T-cells that are considered potential markers for
ystemic and local protective immune responses against inﬂuenza
nfection. Importantly, no adverse side effects or clinical signs of
ecreased well-being of the study animals were observed after
ntratracheal administration of the double-adjuvanted vaccine.
hese increased antigen-speciﬁc immune responses demonstrated
he synergistic effect of the combination of nontoxic concentrations
f SiO2 and c-di-GMP and were in line with the work of Svind-
and et al. [9]. Although mucosal IgG and IgA were induced by the
ingle-adjuvanted vaccine HAC1/c-di-GMP, a higher antigen dose
as required. With regard to the shortage of vaccine supply dur-
ng inﬂuenza pandemics and the focus of new vaccine strategies
n antigen dose-sparing formulations, the double-adjuvanted vac-
ine showed promising results as it provided a dose sparing effect.
owever, 10 g of antigen were required to induce local IgG and
gA in 100% of the vaccinated mice. At a ﬁrst view, systemic vaccina-
ion seemed to be more effective than local vaccination regarding
he antigen dose required to induce systemic HAI and IgG titers.
n the contrary, 1 g HAC1 given systemically was not sufﬁcient
o induce local IgA titers. In fact, this study was  not designed to
ompare dose-sparing effects of local versus systemic applications,
ut rather to evaluate an additive effect of combined adjuvants.
he systemic administration was only used as a control for the vac-
ination protocol as well as antigen stability and not meant as a
omparative group to evaluate superior efﬁcacy of the respiratory
accination to the systemic vaccination.
The importance of mucosal IgA during inﬂuenza infection and its
bility to neutralize virus in infected epithelial cells has previously
een shown [24,25]. Also the role of IgA in cross-protection against
rifted virus strains has been shown to contribute to protection,
lbeit it is not essential [26,27]. New insights into immune protec-
ion have altered second generation inﬂuenza vaccines from being
esigned to induce systemic IgG toward the induction of broader
ross-protective responses against the virus, including other anti-
ody isotypes, such as IgA. This new protection strategy combines
he induction of systemic and local as well as humoral and cellu-
ar immune responses [25]. In this study, the double-adjuvanted
accine demonstrated the ability to induce systemic functional
ntibody responses as well as local cellular immune responses
uggesting the advantage of combining proper adjuvants and the
elevance of immunizing at the site of infection.
Even though a challenge study would be necessary to prove
hat the local and systemic immune responses observed here
an provide protection against inﬂuenza virus infection, there is
onvincing evidence in the literature that the measured immune
esponses discussed above have been linked to protective efﬁ-
acy [28–30]. For example, Liu et al. compared different routes
f immunization and their effect on local and systemic immune
esponses and combined this with lung protection against an
nﬂuenza infection [29]. Their results regarding the induction of
ucosal IgA, serum IgG and systemic HAI titers after vaccine
dministration into the lower airways of the lung were in line
ith the results presented above. They detected only in the primedntrapulmonary immunization mucosal sIgA in the lung, but not
he intramuscular administration. Furthermore, they observed the
ighest nasal and lung IgG titers in mice primed (and boosted) via
he mucosal route [29]. Of note, the challenge study performed by2 (2014) 3216–3222 3221
Liu et al. demonstrated that the immune responses induced by the
adjuvanted intrapulmonary vaccination were sufﬁcient to protect
against inﬂuenza virus infection and reduce the virus titers in the
lung post infection to levels below detection [29].
It has been shown previously that intranasal administration
of c-di-GMP as an adjuvant for inﬂuenza vaccines can induce
multifunctional inﬂuenza-speciﬁc CD4+ Th1 cells in the spleen of
immunized mice [8,9]. Furthermore, multifunctional Th1 cells have
also been shown to be present in the blood of vaccinated human
volunteers and in the non-inﬂamed normal human lung tissue,
as determined by their potential to produce IL-2, IFN- and/or
TNF- upon re-activation [31,32]. Consistent with the cytokine
proﬁle of inﬂuenza-speciﬁc multifunctional Th1 cells, our study
showed increased IL-2 and IFN- levels in antigen re-stimulated
PCLS of mice vaccinated with HAC1/c-di-GMP. The induction of Th1
cytokines in re-stimulated PCLS indicates that the antigen was  rec-
ognized by HAC1-speciﬁc memory T-cells. These results are in line
with the hypothesis by Jul-Larsen and colleagues who discussed
that addition of an adjuvant improves the efﬁcacy of HAC1 toward
the induction of a robust T-cell response [32].
Additionally, our results aligned with previous studies on
intranasally administered c-di-GMP showing an induction of a Th1-
biased cytokine proﬁle in re-stimulated splenocytes against target
antigen [8,9,33]. Yet, our study also showed a mild induction of the
Th2 cytokine IL-5 and the anti-inﬂammatory cytokine IL-10 in re-
stimulated PCLS of intratracheally c-di-GMP-vaccinated mice. The
fold induction of the Th1 cytokines for the double-adjuvanted vac-
cinated mice, however, far exceeded the level of Th2 cytokines that
were induced (IFN-:IL-5, about 119-fold; IFN-:IL-10, about 39-
fold). Nevertheless, the double-adjuvanted vaccine, as well as the
c-di-GMP admixed antigen, induced IL-10 secretion in PCLS upon
antigenic re-stimulation which exceeded the non-stimulated IL-
10 baseline level. Among other cytokines, IL-10 can be released by
inﬂuenza-speciﬁc CD4+ memory T-cells and has been described as
having a putatively crucial role in regulating inﬂammation during
acute inﬂuenza infection [34]. The fact that the double-adjuvanted
vaccine induced IL-10-competent cells might also contribute to a
reduced level of inﬂammation in the lungs with repeated exposure
to the virus post vaccination.
Overall, the data presented in the current study demonstrate
that the double-adjuvanted HAC1 vaccine is immunogenic in the
mouse model when administered intratracheally. Even though the
protective efﬁcacy of the double-adjuvanted HAC1 vaccine needs
to be evaluated in a relevant animal model, the present study
demonstrates that the double-adjuvanted HAC1 induces systemic
functional antibody response as well as local humoral and cellu-
lar immune responses when administered via the respiratory tract,
indicating potential for future needle-free vaccine applications.
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